X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3637) 3637
Book / eBook (3) 3
Book Chapter (3) 3
Conference Proceeding (3) 3
Dissertation (1) 1
Government Document (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2586) 2586
male (2074) 2074
neurosciences (1961) 1961
parkinson's disease (1854) 1854
humans (1642) 1642
parkinsonian disorders - metabolism (1560) 1560
disease models, animal (1128) 1128
rats (1123) 1123
parkinsonian disorders - pathology (1021) 1021
parkinsonian disorders - physiopathology (1014) 1014
female (960) 960
mice (933) 933
dopamine - metabolism (885) 885
parkinsonian disorders - chemically induced (878) 878
parkinsonian disorders - drug therapy (846) 846
neurology (740) 740
clinical neurology (725) 725
dopamine (717) 717
neurons (657) 657
parkinsons-disease (640) 640
parkinsonian disorders - genetics (628) 628
disease (603) 603
rats, sprague-dawley (596) 596
mice, inbred c57bl (567) 567
neurons - metabolism (560) 560
substantia-nigra (551) 551
corpus striatum - metabolism (530) 530
parkinson’s disease (514) 514
substantia nigra - metabolism (511) 511
brain (501) 501
basal ganglia (482) 482
tyrosine 3-monooxygenase - metabolism (468) 468
middle aged (450) 450
oxidative stress (445) 445
analysis (435) 435
substantia nigra - drug effects (429) 429
brain - metabolism (424) 424
neurons - drug effects (420) 420
aged (415) 415
mptp (414) 414
corpus striatum - drug effects (410) 410
oxidopamine (395) 395
alpha-synuclein (381) 381
biochemistry & molecular biology (379) 379
substantia nigra - pathology (364) 364
nervous system (363) 363
rats, wistar (360) 360
neurodegeneration (355) 355
neurons - pathology (355) 355
parkinsonism (337) 337
movement disorders (335) 335
immunohistochemistry (317) 317
brain - pathology (316) 316
motor activity - drug effects (313) 313
neuroprotective agents - pharmacology (311) 311
6-hydroxydopamine (306) 306
pharmacology & pharmacy (295) 295
neurodegenerative diseases (286) 286
substantia nigra (284) 284
dopaminergic-neurons (277) 277
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (271) 271
nervous system diseases (268) 268
striatum (268) 268
substantia nigra - physiopathology (268) 268
parkinsons disease (260) 260
adult (259) 259
neuroprotection (256) 256
parkinsonian disorders - diagnostic imaging (255) 255
dose-response relationship, drug (249) 249
parkinsonian disorders - therapy (249) 249
oxidopamine - toxicity (248) 248
corpus striatum - pathology (240) 240
mutation (240) 240
cell biology (219) 219
brain - drug effects (215) 215
parkinsonian disorders - complications (215) 215
antiparkinson agents - pharmacology (212) 212
time factors (210) 210
expression (207) 207
parkinson disease (207) 207
apoptosis (204) 204
dopaminergic neurons - metabolism (201) 201
cells, cultured (199) 199
alpha-synuclein - metabolism (198) 198
parkinsonian disorders - diagnosis (194) 194
phenols (194) 194
alzheimers-disease (193) 193
corpus striatum - physiopathology (192) 192
degeneration (191) 191
biomedicine (189) 189
neurotoxicity (185) 185
progressive supranuclear palsy (185) 185
in-vivo (182) 182
l-dopa (180) 180
mouse model (180) 180
parkinsonian disorders (179) 179
tyrosine (176) 176
aged, 80 and over (174) 174
physiological aspects (173) 173
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3599) 3599
Japanese (26) 26
German (15) 15
Russian (11) 11
French (8) 8
Chinese (7) 7
Spanish (7) 7
Hungarian (4) 4
Polish (3) 3
Ukrainian (3) 3
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 2018, Volume 557, Issue 7704, pp. 177 - 182
Loss of dopamine in Parkinson's disease is hypothesized to impede movement by inducing hypo-and hyperactivity in striatal spiny projection neurons (SPNs) of... 
MOVEMENT-DISORDERS | OPTOGENETIC CONTROL | DOPA-INDUCED DYSKINESIA | BASAL GANGLIA | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | RECEPTOR OCCUPANCY | PROJECTION NEURONS | BRAIN | STRIATUM | Neostriatum - physiopathology | Male | Receptors, Dopamine D2 - metabolism | Receptors, Dopamine D1 - metabolism | Parkinsonian Disorders - metabolism | Dopamine - deficiency | Receptors, Dopamine D1 - agonists | Female | Neostriatum - metabolism | Neurons - metabolism | Calcium Signaling | Dopamine - metabolism | Levodopa - pharmacology | Movement - drug effects | Neostriatum - pathology | Parkinsonian Disorders - physiopathology | Receptors, Dopamine D2 - agonists | Dyskinesias - pathology | Dyskinesias - physiopathology | Dyskinesias - etiology | Dyskinesias - metabolism | Animals | Parkinsonian Disorders - pathology | Models, Biological | Mice | Levodopa - metabolism | Physiological aspects | Neural circuitry | Parkinson's disease | Health aspects | Movement disorders | Dihydroxyphenylalanine | Basal ganglia | Medical imaging | Dopamine | Neurodegenerative diseases | Hyperactivity | Abnormalities | Medical treatment | Parkinsons disease | Central nervous system diseases | Ganglia | Depletion | Dopamine D1 receptors | Psychopharmacology | Neostriatum | Clusters | Software | Levodopa | Dopa | Dopamine D2 receptors | Dyskinesia
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 38, pp. E5308 - E5317
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2008, Volume 105, Issue 7, pp. 2693 - 2698
Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology. Previously,... 
Brain | Eclosion | Phenotypes | Disease models | Neurons | Drosophila | Mortality | Parkinson disease | Genetic mutation | Genotypes | Dopaminergic neuron | Parkinson's disease | KINASE-ACTIVITY | MULTIDISCIPLINARY SCIENCES | MECHANISMS | dopaminergic neuron | NEURODEGENERATIVE DISEASES | DEGENERATION | arkinson's disease | FLY | COMMON LRRK2 MUTATION | TARGETED GENE-EXPRESSION | NEURONS | NEUROPATHOLOGY | MELANOGASTER | Retina - metabolism | Dopamine - genetics | Nerve Degeneration - genetics | Gait Disorders, Neurologic - genetics | Drosophila melanogaster - genetics | Nerve Degeneration - metabolism | Drosophila melanogaster - metabolism | Parkinsonian Disorders - metabolism | Gait Disorders, Neurologic - pathology | Parkinsonian Disorders - genetics | Dopamine - metabolism | Protein-Serine-Threonine Kinases - metabolism | Disease Models, Animal | Animals, Genetically Modified | Gene Expression Regulation | Protein-Serine-Threonine Kinases - genetics | Drosophila melanogaster - ultrastructure | Microscopy, Electron | Nerve Degeneration - pathology | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | Dopa Decarboxylase - metabolism | Gait Disorders, Neurologic - metabolism | Animals | Parkinsonian Disorders - pathology | Dopa Decarboxylase - genetics | Parkinsonism | Usage | Genetic aspects | Models | Biological Sciences
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2013, Volume 110, Issue 42, pp. E4016 - E4025
Journal Article
Neurobiology of disease, ISSN 0969-9961, 2012, Volume 46, Issue 3, pp. 527 - 552
...). The present review is a comprehensive and up-to-date assessment of such dysfunction in PD and related disorders... 
Neurology | Parkinson's disease | Dopamine | Neurodegenerative diseases | Serotonin | Lewy body disease | Electrophysiology | Psychophysics | Olfaction | Aging | Genetics | Acetylcholine | Norepinephrine | Dystonia | Functional imaging | PRIMATE ORBITOFRONTAL CORTEX | MULTIPLE SYSTEM ATROPHY | SMELL IDENTIFICATION TEST | G2019S MUTATION CARRIERS | NIGROSTRIATAL DOPAMINERGIC DENERVATION | AMYOTROPHIC-LATERAL-SCLEROSIS | ODOR DETECTION PERFORMANCE | NEUROSCIENCES | 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE RAT MODEL | DRUG-INDUCED PARKINSONISM | PROGRESSIVE SUPRANUCLEAR PALSY | Parkinson Disease - complications | Parkinsonian Disorders - physiopathology | Diagnosis, Differential | Olfactory Bulb - physiopathology | Parkinsonian Disorders - complications | Humans | Parkinsonian Disorders - psychology | Neurotransmitter Agents - metabolism | Olfactory Mucosa - physiopathology | Parkinson Disease - genetics | Parkinson Disease - physiopathology | Parkinson Disease - psychology | Neuropsychological Tests | Olfactory Pathways - physiopathology | Smell - physiology | Phenotype | Animals | Olfaction Disorders - physiopathology | Olfactory Mucosa - pathology | Parkinsonian Disorders - genetics | Olfaction Disorders - etiology | Olfactory Pathways - pathology | Index Medicus | Oxidative stress | Animal models | Data processing | Nervous system | Inflammation | Dysautonomia | Olfactory thresholds | Olfactory system | Reviews | Sleep | Olfactory bulb | Brain injury | Movement disorders
Journal Article
Clinical and experimental pharmacology & physiology, ISSN 1440-1681, 07/2007, Volume 34, Issue 7, pp. 555 - 565
SUMMARY • The exact nature of oestrogen (positive, negative or no effect) in the dopaminergic neurodegenerative disorder Parkinson's disease is controversial... 
oestrogen | neurodegeneration | Parkinson's disease | dopamine | Oestrogen | Dopamine | Neurodegeneration | SYSTEM | PHYSIOLOGY | METHAMPHETAMINE-INDUCED NEUROTOXICITY | FEMALE MICE | MALE-MICE | RISK | COFFEE CONSUMPTION | SUBSTANTIA-NIGRA | MPTP-INDUCED NEUROTOXICITY | POSTMENOPAUSAL ESTROGEN | IN-VIVO | PHARMACOLOGY & PHARMACY | Neuroprotective Agents - therapeutic use | Neurons - pathology | Estrogens - pharmacology | Substantia Nigra - pathology | Humans | Basal Ganglia - metabolism | Parkinson Disease - drug therapy | Substantia Nigra - metabolism | Nerve Degeneration - metabolism | Neuroprotective Agents - metabolism | Estrogens - therapeutic use | Parkinsonian Disorders - metabolism | Neuroprotective Agents - pharmacology | Parkinsonian Disorders - drug therapy | Neurons - metabolism | Parkinson Disease - metabolism | Estrogens - metabolism | Dopamine - metabolism | Disease Models, Animal | Parkinson Disease - pathology | Basal Ganglia - pathology | Nerve Degeneration - pathology | Substantia Nigra - drug effects | Animals | Parkinsonian Disorders - pathology | Nerve Degeneration - drug therapy | Basal Ganglia - drug effects | Parkinson Disease, pathology | Parkinsonian Disorders, pathology | Parkinsonian Disorders, metabolism | Neurons, metabolism | Nerve Degeneration, drug therapy | Substantia Nigra, metabolism | Nerve Degeneration, metabolism | Basal Ganglia, metabolism | Dopamine, metabolism | Estrogens, therapeutic use | Neurons, pathology | Substantia Nigra, pathology | Parkinson Disease, drug therapy | Nerve Degeneration, pathology | Neuroprotective Agents, metabolism | Neuroprotective Agents, therapeutic use | Parkinsonian Disorders, drug therapy | Basal Ganglia, pathology | Substantia Nigra, drug effects | Neuroprotective Agents, pharmacology | Parkinson Disease, metabolism | Estrogens, pharmacology | Estrogens, metabolism | Basal Ganglia, drug effects | Estrogen
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2016, Volume 94, pp. 179 - 195
... ' s disease (PD), at least in the first and middle phases of the disorder ( Carlsson, 2002; Connolly and Lang, 2014 ). However, L-DOPA administration only ameliorates... 
Neurology | AIMs | NF-κB | CB1 | COX-2 | pAcH3 | LID | TRPV-1 | Neuroinflammation | ERK 1/2 | Cannabinoid | PPAR gamma | Anandamide | NITRIC-OXIDE SYNTHASE | PROLIFERATOR-ACTIVATED RECEPTORS | GAMMA PPAR-GAMMA | ABNORMAL INVOLUNTARY MOVEMENTS | NEUROSCIENCES | MESSENGER-RNA LEVELS | RAT MODEL | NF-kappa B | LEVODOPA-INDUCED DYSKINESIA | NF-KAPPA-B | CANNABINOID RECEPTOR AGONIST | PARKINSONS-DISEASE | Endocannabinoids - metabolism | Tyrosine 3-Monooxygenase - metabolism | Dyskinesia, Drug-Induced - physiopathology | Anti-Dyskinesia Agents - toxicity | Capsaicin - pharmacology | Male | NF-kappa B - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Oxidopamine | PPAR gamma - metabolism | TRPV Cation Channels - metabolism | Arachidonic Acids - metabolism | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Parkinsonian Disorders - physiopathology | Mice, Inbred C57BL | Cannabidiol - pharmacology | Capsaicin - analogs & derivatives | Levodopa - toxicity | Dyskinesia, Drug-Induced - pathology | Polyunsaturated Alkamides - metabolism | Brain - drug effects | Receptor, Cannabinoid, CB1 - metabolism | Anti-Dyskinesia Agents - pharmacology | Animals | Parkinsonian Disorders - pathology | Cyclooxygenase 2 - metabolism | Brain - pathology | Histones - metabolism | Physiological aspects | Phenols | COX-2 inhibitors | Fatty acids | Movement disorders
Journal Article